Two studies published earlier this month in Nature have demonstrated how Inostics' BEAMing digital PCR/flow cytometry technology can be used to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure is observed.
A new assay dubbed Allele Specific Locked Nucleic Acid quantitative PCR, or ASLNAqPCR, can identify and quantitate KRAS and BRAF mutations from a variety of sample types with 100 percent specificity, and greater accuracy and higher analytical sensitivity than Sanger sequencing, a
After a survey of UK oncologists revealed that access hurdles and high costs associated with biomarker testing are limiting their ability to prescribe personalized treatments, Merck Serono has issued a "call to action" for the government and pharmaceutical industry to work togeth
Originally published Jan. 16.
In a pharmacogenetic investigation conducted by researchers in the Netherlands, Bayer's Nexavar was not able to improve survival in patients with KRAS-mutated non-small cell lung cancer.
The headline and this story have been updated to reflect that BMS and Lilly have submitted to the FDA retrospective analysis on Erbitux's efficacy in colorectal cancer patients with wild-type KRAS mutations, which the agency may use to update the drug label.